Skip to main content

Table 2 Distribution of inhibitory molecules on CD4+ and CD8+ T cells in BM aspirates and PB of myeloma patients and healthy persons

From: T cells in multiple myeloma display features of exhaustion and senescence at the tumor site

  BM PB
Healthy
Median % (IQR)
Myeloma
Median % (IQR)
Healthy
Median % (IQR)
Myeloma
Median % (IQR)
CD4+ T cells
 PD-1+ 44.4 (17.7–60.3) 64.5 (36.8–77.4) * 47.2 (21.6–60.2) 66.6 (48.0–74.8) *
 2B4+ 30.3 (7.3–43.2) 36.1 (28.4–47.3) n.s. 33.7 (17.8–45.2) 33.4 (19.1–44.6) n.s.
 CD160+ 29.4 (8.3–33.2) 30.8 (23.4–39.0) n.s. 33.1 (10.5–37.3) 30.6 (16.8–38.9) n.s.
 CTLA-4+ 43.5 (29.4–56.6) 60.3 (52.2–64.4) * 48.8 (37.9–59.6) 56.7 (35.6–65.4) n.s.
CD8+ T cells
 PD-1+ 60.7 (50.8–69.4) 73.0 (65.7–86.8) * 50.20 (42.0–66.7) 74.1 (57.8–81.9) *
 2B4+ 42.0 (24.1–46.1) 58.5 (43.1–69.0) * 56.50 (36.7–69.6) 59.4 (49.3–70.3) n.s.
 CD160+ 38.7 (22.9–49.8) 56.4 (44.4–64.8) * 44.30 (16.6–57.8) 49.4 (40.5–59.2) n.s.
 CTLA-4+ 53.1 (44.9–59.6) 65.8 (61.9–67.9) ** 58.55 (43.5–64.2) 64.7 (60.6–71.8) n.s.
  1. Flow cytometric analyses of inhibitory molecules are presented as median percentage of cells expressing the respective molecules with IQR (n = 7–12). Statistical significance was calculated using Mann-Whitney U test
  2. n.s. not significant
  3. *p < 0.05; **p < 0.01